MedPath

Study to Document the Phenomenon of Vitamin D Deficiency and Its Added Value in Patients with Low-energy Osteoporotic Hip Fracture, in Daily Practice in Greece.

Recruiting
Conditions
Vitamin D Deficiency
Osteoporosis
Bone Loss, Age-Related
Fracture of Hip
Registration Number
NCT06643650
Lead Sponsor
National and Kapodistrian University of Athens
Brief Summary

Vitamin D, through its action on calcium metabolism, is essential for bone physiology. Vitamin D deficiency can affect muscle function and increase the risk of falls in the elderly, while severe deficiency is common in patients with fragility fractures. Vitamin D and calcium supplementation, in addition to anti-osteoporosis treatment after surgery or conservative treatment, can ensure optimal recovery and survival, especially in patients with a hip fracture.

The goal of vitamin D supplementation is to bring the serum 25-(OH)-D concentration above 30 ng/ml.

Clinical pathways have been developed to support orthopedic surgeons in improving the medical management of patients after orthopedic/surgical fracture management. Pathways include advising primary care physicians and orthopedic surgeons on diagnostic and therapeutic approaches, promoting their appropriate use without compromising quality of care, and educating patients on non-pharmacological management of their disease (physical therapy, lifestyle habits life and nutrition).

This is an observational cohort study that will record data on the use of vitamin D in daily practice in patients with low-energy fractures.

The aim of this study is to measure vitamin D levels in the patient and provide these patients according to daily practice with appropriate supplementation for a period of one year, observing if there is a good functional outcome and a reduction in the risks of new fractures.

Detailed Description

Not available

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Patients > 18 years old
  • Patients with a low energy fracture
  • Vitamin D levels < 30 ng/ml
  • Patients with available medical history before and after initiation of study treatment
  • Patients providing informed consent for this study
Exclusion Criteria
  • Pregnant or breastfeeding women
  • Patients receiving different osteoporosis treatment
  • Patients with known hypersensitivity to vitamin D
  • Patients participating in another similar study at the same time with other drugs
  • Patients with vitamin D contraindications according to the medical instructions for use
  • Patients with a fracture due to a traffic accident

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Evaluation of Vitamin D levels of the patients after receiving vitamin D supplementation1 month, 3 months, 6 months and 12 months

Measurement of 25(OH)D vitamin

Evaluation of BMD of the patients after receiving vitamin D supplementation12 months

Measurement of Bone Mineral Density

Secondary Outcome Measures
NameTimeMethod
PTH1 month, 3 months, 6 months and 12 months

Measurement of blood test of Parathyroid Hormone

TSH1 month, 3 months, 6 months and 12 months

Measurement of blood test of Thyroid-stimulating Hormone

Ca1 month, 3 months, 6 months and 12 months

Measurement of blood test of Calcium levels

P1 month, 3 months, 6 months and 12 months

Measurement of blood test of Phosphorus levels

ALP1 month, 3 months, 6 months and 12 months

Measurement of blood test of Alkaline phosphatase levels

Al1 month, 3 months, 6 months and 12 months

Measurement of blood test of Albumin levels

Mg1 month, 3 months, 6 months and 12 months

Measurement of blood test of Magnesium levels

Trial Locations

Locations (1)

KAT General Hospital of Attika

🇬🇷

Kifisia, Attika, Greece

© Copyright 2025. All Rights Reserved by MedPath